Mission Statement

Mucosis’s mission is to discover and develop mucosal vaccines for the prevention and treatment of infectious diseases. It is our goal to transform excellent research into novel high-value vaccines which serve patients in need of an efficacious therapy and improved patient convenience.

30.09.14 Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum
more >

22.05.14 Mucosis receives financial support from the Dutch government for its SynGEM® program
more >

15.04.14 Mucosis announces a strategic partnership with Changchun BCHT Biotechnology of China and raises additional capital
more >

12.08.13 Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines
more >

16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >

08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >